IPhone / Mobile Compatible

Viewport Meta

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

WordPress

Font Awesome

Organization Schema

Sitelinks Search Box

Person Schema

Chief Medical Officer

Carl Sadowsky

Director of Project Management

Dennis Nilan

Director of Marketing & Communications

Justine LaVoye

Operations Consultant

Bill Gordon

Vice President

David Crockford

Vice President Clinical Development

Joyce Myers

Chief Financial Officer

Robert Weinstein

Managing Director

Susanne Wilke

Lee Goldstein

Michael Kaswan

Greater Boston Area Companies With Fewer Than 100 Employees (Top 10K)

United States Health Care Companies (Top 10K)

Northeastern US Companies With Fewer Than 10 Employees (Top 10K)

Health Diagnostics Companies With Less Than $50M in Revenue (Top 10K)

Cognoptix  is creating and developing an innovative, non-invasive eye test to assist in the early diagnosis of Alzheimer's Disease. Cognoptix's goal is to provide clinicians with a quick, predictive, reliable, inexpensive, and widely available test, enabling early diagnosis and treatment.

The company was founded in 2001 and headquartered in Marlborough, Massachusetts.

LaunchPad Venture

Venture Round - Cognoptix

Alopexx

Inventages Venture Capital Investment Inc.

Series D - Cognoptix

Debt Financing - Cognoptix

Series C - Cognoptix

Series B - Cognoptix

Series A - Cognoptix

Seed Round - Cognoptix

Angel Round - Cognoptix

Marlborough

Massachusetts

United States

North America

Cognoptix

Alzheimer's Disease Therapeutics and Diagnostics Market Overview for 2028

Europe Alzheimer's Disease Therapeutics & Diagnostics Market Analysis by 2028

Dr. Marwan Sabbagh Joins the Cognoptix Scientific Advisory Board

United Kingdom

Europe

HTML5

Lightbox

Office 365

F5 NGINX

Apache Server

Comodo PositiveSSL Certificates

Google Drive

Microsoft Outlook

Google Fonts

Wordpress

Cognoptix is pioneering a new way to detect Alzheimer's disease through a low-cost, practical, and non-invasive eye scan that detects beta-amyloid deposits in the lens. Their system can detect amyloid years or decades before it appears in the brain.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 9, 2024 2:28 AM	487d4ecf
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 9, 2024 2:28 AM	a800bdc6
company summary	general
signals	general
crunchbase trigger	general	Oct 28, 2024 1:51 PM	b59c65fd
crunchbase profile	general	Oct 29, 2024 7:33 AM	dd482ec3
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	c45f5357
peers	general
news basic	general	Mar 9, 2024 2:28 AM	22f94c82
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COGN

COM:COGNOPTIX

Cognoptix